GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
Ucap Cloud Information Technology Co.,Ltd
688228
Yangtze Optical Electronic
688143
CN Stock MarketDetailed Quotes
300181 Zhejiang Jolly Pharmaceutical
- 14.74
- +0.03+0.20%
Market Closed Jan 24 15:00 CST
10.34BMarket Cap19.97P/E (TTM)
14.88High14.50Low111.88KlotVolume14.71Open14.71Pre Close164.00MTurnover1.86%Turnover Ratio27.00P/E (Static)701.39MShares18.5052wk High3.98P/B8.86BFloat Cap7.9152wk Low17.65Limit Up601.08MShs Float18.50Historical High11.77Limit Down2.58%Amplitude1.02Historical Low0.45Dividend TTM14.66Avg Price56.49KlotAsk3.05%Div YieldTTM100Lot Size51.61KlotBid
Zhejiang Jolly Pharmaceutical News
Zhejiang Jolly Pharmaceutical (300181.SZ): The first transfer of shares under the 2024 employee stock ownership plan has been completed through non-trade transfer.
On January 15th, Gelonghui reported that Zhejiang Jolly Pharmaceutical (300181.SZ) announced that as of the date of this announcement, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. The 5.975 million shares of the company's stocks held by the company’s repurchase special securities account were transferred on January 14, 2025, through a non-trading transfer to "Zhejiang Jolly Pharmaceutical Co., Ltd. - 2024 Employee Stock Ownership Plan." The number of transferred shares accounts for 0.85% of the total share capital of the company as of the announcement date of the employee stock ownership plan draft, with a transfer price of 8.07 yuan per share.
Zhejiang Jolly Pharmaceutical (300181.SZ) granted 5.855 million shares of restricted stocks at a grant price of 8.07 yuan per share.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that the restricted stock incentive plan for 2024 stipulates the restrictions on stocks...
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin tablets are proposed to be selected for the national Chinese Patent Medicine procurement alliance's centralized purchasing.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that recently, the company and its controlling subsidiary Qinghai Zhuofeng Cordyceps Sinensis Pharmaceutical...
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin capsules have officially been launched for sale.
On December 24, Gelonghui reported that Zhejiang Jolly Pharmaceutical (300181.SZ) announced on the investor interaction platform that the company’s Bailin capsules have officially launched for sale.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Seems To Use Debt Quite Sensibly
Jolly Pharmaceutical to Take Controlling Stake in Lingyi Biotech in Cooperation Deal; Shares Up 3%
Zhejiang Jolly Pharmaceutical (300181.SZ): Signed a global strategy cooperation framework agreement with Lingyi Biotechnology.
On November 20th, Jolly Pharmaceutical (300181.SZ) announced that the company has signed a "Strategic Cooperation Framework Agreement" with Lingyi (Hangzhou) Biotechnology Co., Ltd. According to the agreement, the two parties will establish a long-term and in-depth strategic cooperation relationship. The main areas of cooperation include equity cooperation, research and development cooperation, sales cooperation, and product cooperation. In terms of equity cooperation, Jolly Pharmaceutical will increase its capital to become the second largest shareholder of Lingyi Biotech (Series A round). In terms of research and development cooperation, the two parties will jointly develop innovative drugs for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Jumps 6.5% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Zuoli Pharmaceuticals: third quarter report 2024
Zhejiang Jolly Pharmaceutical (300181.SZ) plans to launch an employee stock ownership plan in 2024.
Zhejiang Jolly Pharmaceutical (300181.SZ) released the 2024 employee stock ownership plan (draft), the employee stock ownership plan is expected to raise...
Zhejiang Jolly Pharmaceutical (300181.SZ) plans to launch a restricted stock incentive plan for 2024.
Zhejiang Jolly Pharmaceutical (300181.SZ) released the 2024 restricted stock incentive plan (draft), intending to incentivize...
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Surges 7.5%; Individual Investors Who Own 49% Shares Profited Along With Insiders
Potential Upside For Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Not Without Risk
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
Zuli Pharmaceuticals: Earnings Forecast for the First Three Quarters of 2024
Zhejiang Jolly Pharmaceutical (300181.SZ) has cumulatively repurchased 1.24% of the shares, with a total investment of 0.127 billion yuan.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that as of August 31, 2024, the company will trade through centralized bidding...
Could The Market Be Wrong About Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Given Its Attractive Financial Prospects?